Skip to main content
All lobbying filings

STANTON PARK GROUP

Lobbying for BRAEBURN PHARMACEUTICALS, INC. · pharmaceutical company

 Filing 3rd Quarter - Report
3rd Quarter (July 1 - Sep 30) 2025 · New Jersey · House · Senate · $50,000.00 income · posted Oct 20, 2025

Official filing document

 Lobbying activity 1
Health Issues

Reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; patient access to practitioner-administered therapies Reauthorization of the Support Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem